The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 5, 2008, Pages 739-749

  Swift, Lonnie P ^a   Cutts, Suzanne M ^a   Nudelman, Abraham ^b   Levovich, Inessa ^c   Rephaeli, Ada ^c   Phillips, Don R ^a  

^a LA TROBE UNIVERSITY   (Australia)

^b BAR ILAN UNIVERSITY   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Doxorubicin; Drug DNA adducts; Formaldehyde; Sobuzoxane; Topoisomerase II

Indexed keywords

ACLARUBICIN; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; FORMALDEHYDE; MALEIMIDE; MERBARONE; PIVALOYLOXYMETHYL BUTYRATE; SOBUZOXANE; STAUROSPORINE; SURAMIN;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG INHIBITION; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; COMET ASSAY; DNA ADDUCTS; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DOXORUBICIN; DRUG SYNERGISM; FLOW CYTOMETRY; FORMALDEHYDE; HL-60 CELLS; HUMANS; PIPERAZINES; SCINTILLATION COUNTING;

EID: 39749159086     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0528-2     Document Type: Article

References (53)

1. DeVita VT, Hellman S, Rosenberg SA (eds) (2005) Cancer: principles & practice of oncology. Lippincott Williams and Wilkins, Philadelphia
2. Taatjes DJ, Gaudiano G, Resing K, Koch TH (1997) Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs Adriamycin and daunomycin. J Med Chem 40:1276-1286
3. Doroshow JH (1995) Role of reactive-oxygen metabolism in cardiac toxicity of anthracycline antibiotics. In: Priebe W (ed) Anthracycline antibiotics: new analogues, methods of delivery, and mechanisms of action. American Chemical Society, Washington, DC, pp 259-267
4. Berman E, McBride M (1992) Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 79:3267-3273
5. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727-741
6. Cutts SM, Swift LP, Rephaeli A, Nudelman A, Phillips DR (2005) Recent advances in understanding and exploiting the activation of anthracyclines by formaldehyde. Curr Med Chem Anti-Cancer Agents 5:431-447
7. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351-375
8. Pommier Y (1995) DNA Topoisomerases and their inhibition by anthracyclines. Anthracycline antibiotics: new analogues, methods of delivery, and mechanisms of action. American Chemical Society, Washington, DC, pp 183-203
9. Sordet O, Khan QA, Kohn KW, Pommier Y (2003) Apoptosis induced by topoisomerase inhibitors. Curr Med Chem Anti-Cancer Agents 3:271-290
10. Zunino F, Capranico G (1990) DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anticancer Drug Des 5:307-317
11. Wang J, Gao YG, Liaw CY, Li YK (1991) Formaldehyde cross-links daunorubicin and DNA efficiently: HPLC and X-ray diffraction studies. Biochemistry 30:3812-3815
12. Fenick DJ, Taatjes DJ, Koch TH (1997) Doxoform and daunoform: anthracycline-formaldehyde conjugates toxic to resistant tumor cells. J Med Chem 40:2452-2461
13. Zeman SM, Phillips DR, Crothers DM (1998) Characterization of covalent Adriamycin-DNA adducts. Proc Natl Acad Sci USA 95:11561-11565
14. Cullinane C, Cutts SM, Panousis C, Phillips DR (2000) Interstrand cross-linking by Adriamycin in nuclear and mitochondrial DNA of MCF-7 cells. Nucleic Acids Res 28:1019-1025
15. Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM (2006) Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 66:4863-4871
16. Nudelman A, Levovich I, Cutts SM, Phillips DR, Rephaeli A (2005) The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters. J Med Chem 48:1042-1054
17. Swift LP, Cutts SM, Rephaeli A, Nudelman A, Phillips DR (2003) Activation of adriamycin by the pH-dependent Formaldehyde-releasing prodrug hexamethylenetetramine. Mol Cancer Ther 2:189-198
18. Berger JM, Gamblin SJ, Harrison SC, Wang JC (1996) Structure and mechanism of DNA topoisomerase II. [erratum appears in Nature 1996 Mar 14;380(6570):179]. Nature 379:225-232
19. Moro S, Beretta GL, Dal Ben D, Nitiss J, Palumbo M, Capranico G (2004) Interaction model for anthracycline activity against DNA topoisomerase II. Biochemistry 43:7503-7513
20. Liu LF, Rowe TC, Yang L, Tewey KM, Chen GL (1983) Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem 258:15365-15370
21. Larsen AK, Escargueil AE, Skladanowski A (2003) Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 99:167-181
22. Jensen PB, Sorensen BS, Demant EJ, Sehested M, Jensen PS, Vindelov L, Hansen HH (1990) Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res 50:3311-3316
23. Sorensen BS, Sinding J, Andersen AH, Alsner J, Jensen PB, Westergaard O (1992) Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events. J Mol Biol 228:778-786
24. Peters KB, Brown JM (2002) Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res 62:5248-5253
25. Roca J, Ishida R, Berger JM, Andoh T, Wang JC (1994) Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 91:1781-1785
26. Andoh T, Ishida R (1998) Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta 1400:155-171
27. Yoshida M, Maehara Y, Sugimachi K (1999) MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy. Clin Cancer Res 5:4295-4300
28. Inutsuka S, Baba H, Maehara Y, Sugimachi K (1998) MST-16, a novel derivative of bis(2,6-dioxopiperazine), synergistically enhances the antitumor effects of anthracyclines. Cancer Chemother Pharmacol 42:194-200
29. Andoh T (1998) Bis(2,6-dioxopiperazines), catalytic inhibitors of DNA topoisomerase II, as molecular probes, cardioprotectors and antitumor drugs. Biochimie 80:235-246
30. Langer SW, Thougaard AV, Sehested M, Jensen PB (2006) Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone. Cancer Chemother Pharmacol 57:125-128
31. Bojanowski K, Lelievre S, Markovits J, Couprie J, Jacquemin-Sablon A, Larsen AK (1992) Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc Natl Acad Sci USA 89:3025-3029
32. Stein CA (1993) Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 53:2239-2248
33. Kopp R, Pfeiffer A (1990) Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cells. Cancer Res 50:6490-6496
34. Mahoney CW, Azzi A, Huang KP (1990) Effects of suramin, an anti-human immunodeficiency virus reverse transcriptase agent, on protein kinase C. Differential activation and inhibition of protein kinase C isozymes. J Biol Chem 265:5424-5428
35. Lassota P, Singh G, Kramer R (1996) Mechanism of topoisomerase II inhibition by staurosporine and other protein kinase inhibitors. J Biol Chem 271:26418-26423
36. Fortune JM, Osheroff N (1998) Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage. J Biol Chem 273:17643-17650
37. Glover A, Chun HG, Kleinman LM, Cooney DA, Plowman J, Grieshaber CK, Malspeis L, Leyland-Jones B (1987) Merbarone: an antitumor agent entering clinical trials. Invest New Drugs 5:137-143
38. Brewer AD, Minatelli JA, Plowman J, Paull KD, Narayanan VL (1985) 5-(N-phenylcarboxamido)-2-thiobarbituric acid (NSC 336628), a novel potential antitumor agent. Biochem Pharmacol 34:2047-2050
39. Look KY, Blessing JA, Adelson MD, Morris M, Bookman MA (1996) A phase II trial of merbarone (NSC 336628) in the treatment of recurrent epithelial ovarian carcinoma. A gynecologic oncology group study. Am J Clin Oncol 19:7-9
40. Jensen LH, Renodon-Corniere A, Wessel I, Langer SW, Sokilde B, Carstensen EV, Sehested M, Jensen PB (2002) Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition. Mol Pharmacol 61:1235-1243
41. Nudelman A, Ruse M, Aviram A, Rabizadeh E, Shaklai M, Zimrah Y, Rephaeli A (1992) Novel anticancer prodrugs of butyric acid. J Med Chem 35:687-694
42. Cutts SM, Rephaeli A, Nudelman A, Hmelnitsky I, Phillips DR (2001) Molecular basis for the synergistic interaction of Adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res 61:8194-8202
43. Hartley JM, Spanswick VJ, Gander M, Giacomini G, Whelan J, Souhami RL, Hartley JA (1999) Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. Clin Cancer Res 5:507-512
44. Salti GI, Das Gupta TK, Constantinou AI (2000) A novel use for the comet assay: detection of topoisomerase II inhibitors. Anticancer Res 20:3189-3193
45. Olive PL (1989) Cell proliferation as a requirement for development of the contact effect in Chinese hamster V79 spheroids. Radiat Res 117:79-92
46. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271-279
47. Nash T (1953) The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. Biochem J 55:416-421
48. Hasinoff BB, Wu X, Krokhin OV, Ens W, Standing KG, Nitiss JL, Sivaram T, Giorgianni A, Yang S, Jiang Y, Yalowich JC (2005) Biochemical and proteomics approaches to characterize topoisomerase IIalpha cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIalpha. Mol Pharmacol 67:937-947
49. Kagan VE, Kuzmenko AI, Tyurina YY, Shvedova AA, Matsura T, Yalowich JC (2001) Pro-oxidant and antioxidant mechanisms of etoposide in HL-60 cells: role of myeloperoxidase. Cancer Res 61:7777-7784
50. Kagan VE, Yalowich JC, Borisenko GG, Tyurina YY, Tyurin VA, Thampatty P, Fabisiak JP (1999) Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: free radical/antioxidant approach. Mol Pharmacol 56:494-506
51. Cutts SM, Nudelman A, Pillay V, Spencer DMS, Levovich I, Rephaeli A, Phillips DR (2005) Formaldehyde-releasing prodrugs in combination with adriamycin can overcome cellular drug resistance. Oncol Res 15:199-213
52. Liu YP, Araya S, Nakamura T (1992) Arrest in late G2 or prophase of cell cycle induced by 4,4-(1,2-ethanediyl) bis (1-isobutoxycarbonyloxymethyl 2, 6-piperazinedione) (MST-16) in cultured L1210 cells. Int J Cancer 51:792-797
53. Ohno R, Yamada K, Hirano M, Shirakawa S, Tanaka M, Oguri T, Kodera Y, Mitomo Y, Ikeda Y, Yokomaku S (1992) Phase II study: treatment of non-Hodgkin's lymphoma with an oral antitumor derivative of bis(2,6-dioxopiperazine). J Natl Cancer Inst 84:435-438